Webinar on

Cancer Therapy

June 24, 2021

Scientific Program

Keynote Session:

Meetings International -  Conference Keynote Speaker Vladimir Startsev photo

Vladimir Startsev

State pediatric medical university, Krasnodar, Russia

Title:  RESULTS OF ORGAN-SPARRING TREATMENT OF MUSCLE-INVASIVE UROTHELIAL CARCINOMA

Biography:

Vladimir Startsev is the active member of the European Association of Urology and European Society of Surgical Oncology (since 2002), Russian Society of Urologists (since 2001), Russian Association of Oncological Urologists (since 2003) and Professional Association of Russia Andrologists (since 2005). He is also the Professor of the State pediatric medical university (St.-Petersburg, Russia). Corresponding member of Russian Academy of Natural history (Moscow). He also got the Doctoral Degree (MSc) in "Public health and health care" (2007, approved in 2008). He is also the       Founder, business coach and chief manager of the Prime Medical Business Academy (St.-Petersburg, Russia) and Experienced manager in In-patient's care: start-up and management of the new department in regional medical institution (chief manager of the surgical dept., 4.5 years).

Abstract:

In 2018 newly diagnosed urothelial carcinoma (UC) in Russia were registered in 14,446 cases, including 26% pts in stage III-IV. Thus, for every fourth Russian, UC is first detected in a neglected stage. Due to the Guidelines EAU-2017, cystectomy or alternative therapy with bladder preservation used in the treatment of such patients. Chemotherapy in UC pts (M-VAC, GC and other’s) is accompanied with side effects (myelosuppression, dyspepsia, neuroplegia, etc.) that reduce the patient's QoL and, thus, the effectiveness of therapy.Purpose.  To evaluate the effectiveness of regional (i/arterial) ChTer based on platinum drugs in patients with locally advanced UC.MATERIALS AND METHODS. We evaluated the results of regional ChTer in 36 patients with UC in stages T3a-4аN0-1M0G2-3 (8 women, 28 males in median age 65,4±4,2 y.o.) in 1998- 2003 гг. Earlier 21 pts received organ-preserving treatment (TURB + neoadjuvant / adjuvant ChTer), with a short clinical effect. All the patients after the catheterization and angiography of the uroperitoneal arteries received courses (from 6 to 36, median 18) of the regional ChTer (cisplatin, 50 mg / m² and adriablastin, 20 mg / m²) and metostrexate (20 mg / m²) + vinblastine (0, 7 mg / m²) intravenously, by the standard MVAC courses. After finishing of ChTer, the main group of pts was observed during 12-60 months (average 28 months) and over the next 10 years they were studied for their overall survival by a prospective study method.RESULTS. Long-term use of regional ChTer with standard three-week interruptions contributed to partial and complete tumor response in 22 (61.1%) cases. During 24 months after ChTer there were no signs of tumor growth in the bladders of 13 (26.9%) pts. The effect of the treatment was determined by Grade, tumor Stage, the presence of N+ and the previous oncological anamnesis.In 6 (16.7%) cases, with beam and endoscopic confirmation of the tumor progression, we performed salvage cystectomies. Due to the histological report, in 2 bladder’s were not any tumor cells, which was regarded as a "medicinal" pathomorphosis.After 12 months after treatment (16 ChTer courses), 2 patients refused to follow up due to the increase of chronic renal failure: ureterohydronephrosis-II, which required palliative nephrostomy. In first 5 years of follow-up, 10 (27.7%) pts died, among them 6 – with tumor progression. The general toxicity was manifested as moderate myelosuppression (G-I, -II neutropenia and G-II thrombocytopenia). The five-year overall survival (OS) rate was 72.3%, which was consistent with the indicator obtained by foreign researchers. The OS was determined by the tumor Stage of the, the Age and severity of the Concomitant pathology, and the presence of N+.According to results of follow-up, 9 (25.0%) pts survived 10 years with a functioning bladder. The initial stage of UC in 5 cases was pT3aN0M0G2, in 2 - pT3aN0M0G3, in 1 case – pT3bN1M0G2 and 1 – pT4aN0M0G2. At the beginning of the study, all surviving patients were younger than 65.Conclusions. Regional Chemotherapy was effective in more than 61.1% of UC pT3a-4аN0-1M0G2-3 (complete / partial remission, tumor stabilization). Minimization of side effects was achieved due to selective intra-arterial administration of the drug to the tumor, with a decrease of the medication dose. The life expectancy in 25.0% cases exceeded ten years, which is ahead of the average for pts with locally advanced UC and allows us to confidently talk about the need for further research in this direction.

Meetings International -  Conference Keynote Speaker Vladimir Startsev photo

Vladimir Startsev

State Pediatric Medical University, Russia

Title:  Results of organ-sparring treating of muscle-invasive urothelial carsinoma

Biography:

Vladimir Startsev is the active member of the European Association of Urology and European Society of Surgical Oncology (since 2002), Russian Society of Urologists (since 2001), Russian Association of Oncological Urologists (since 2003) and Professional Association of Russia Andrologists (since 2005). He is also the Professor of the State Pediatric Medical University (St. Petersburg, Russia). Corresponding member of Russian Academy of Natural history (Moscow). He also got the Doctoral Degree (MSc) in "Public health and health care" (2007, approved in 2008). He is also the  founder, business coach and chief manager of the Prime Medical Business Academy (St.Petersburg, Russia) and Experienced manager in In-patient's care: start-up and management of the new department in regional medical institution (chief manager of the surgical dept., 4.5 years).

Abstract:

In 2018 newly diagnosed urothelial carcinoma (UC) in Russia were registered in 14,446 cases, including 26% pts in stage III-IV. Thus for every fourth Russian, UC is first detected in a neglected stage. Due to the Guidelines EAU-2017, cystectomy or alternative therapy with bladder preservation used in the treatment of such patients. Chemotherapy in UC pts (M-VAC, GC and other’s) is accompanied with side effects (myelosuppression, dyspepsia, neuroplegia, etc.) that reduce the patient's QoL and thus the effectiveness of therapy.Purpose. To evaluate the effectiveness of regional (i/arterial) ChTer based on platinum drugs in patients with locally advanced UC.
 
Materials and Methods: We evaluated the results of regional ChTer in 36 patients with UC in stages T3a-4аN0-1M0G2-3 (8 women, 28 males in median age 65,4±4,2 y.o.) in 1998- 2003 гг. Earlier 21 pts received organ-preserving treatment (TURB + neoadjuvant/adjuvant ChTer), with a short clinical effect. All the patients after the catheterization and angiography of the uroperitoneal arteries received courses (from 6 to 36, median 18) of the regional ChTer (cisplatin, 50 mg/m² and adriablastin, 20 mg/m²) and metostrexate (20mg/m²)+vinblastine (0, 7 mg/m²) intravenously, by the standard MVAC courses. After finishing of ChTer, the main group of pts was observed during 12-60 months (average 28 months) and over the next 10 years they were studied for their overall survival by a prospective study method.
 
Results: Long-term use of regional ChTer with standard three-week interruptions contributed to partial and complete tumor response in 22 (61.1%) cases. During 24 months after ChTer there were no signs of tumor growth in the bladders of 13(26.9%) pts. The effect of the treatment was determined by Grade, tumor Stage, the presence of N+ and the previous oncological anamnesis.In 6(16.7%) cases, with beam and endoscopic confirmation of the tumor progression, we performed salvage cystectomies. Due to the histological report, in 2 bladder’s were not any tumor cells, which was regarded as a "medicinal" pathomorphosis. After 12 months after treatment (16 ChTer courses), 2 patients refused to follow up due to the increase of chronic renal failure: ureterohydronephrosis-II which required palliative nephrostomy. In first 5 years of follow-up, 10(27.7%) pts died, among them 6 with tumor progression. The general toxicity was manifested as moderate myelosuppression (G-I,II neutropenia and G-II thrombocytopenia). The five-year overall survival (OS) rate was 72.3%, which was consistent with the indicator obtained by foreign researchers. The OS was determined by the tumor Stage of the, the age and severity of the concomitant pathology, and the presence of N+. According to results of follow-up, 9(25.0%) pts survived 10 years with a functioning bladder. The initial stage of UC in 5 cases was pT3aN0M0G2, in 2-pT3aN0M0G3, in 1case–pT3bN1M0G2 and 1–pT4aN0M0G2. At the beginning of the study, all surviving patients were younger than 65.
 
Conclusions: Regional Chemotherapy was effective in more than 61.1% of UC pT3a-4аN0-1M0G2-3 (complete/partial remission, tumor stabilization). Minimization of side effects was achieved due to selective intra-arterial administration of the drug to the tumor, with a decrease of the medication dose. The life expectancy in 25.0% cases exceeded ten years, which is ahead of the average for pts with locally advanced UC and allows us to confidently talk about the need for further research in this direction.

 

Meetings International -  Conference Keynote Speaker Huang Wei Ling photo

Huang Wei Ling

Medical Acupuncture and Pain Management Clinic. Brazil

Title: Chakras and energy deficiencies in the genesis of breast cancer

Biography:

Huang Wei Ling, born in Taiwan, raised and graduated in medicine in Brazil, specialist in infectious and parasitic diseases, a General Practitioner and Parenteral and Enteral Medical Nutrition Therapist. Once in charge of the Hospital Infection Control Service of the City of Franca’s General Hospital, she was responsible for the control of all prescribed antimicrobial medication and received an award for the best paper presented at the Brazilian Hospital Infection Control Congress in 1998. Since 1997, she works with the approach and treatment of all chronic diseases in a holistic way, with treatment guided through the teachings of Traditional Chinese Medicine and Hippocrates. Researcher in the University of Sao Paulo, in the Ophthalmology department from 2012 to 2013.Author of the theory Constitutional Homeopathy of the Five Elements Based on Traditional Chinese Medicine. Author of more than 60 publications about treatment of variety of diseases rebalancing the internal energy using Hippocrates thoughts.

Abstract:

Introduction: Breast cancer is the most common cancer-affecting women worldwide. Western current perspectives are starting to comprehend cancer as a systemic disease from the start. In TCM, the formation of cancer is associated energy deficiencies with Heat retention. Spleen deficiency is one of the major causes of formation of Phlegm leading to the formation of tumors. There are studies associating the five elements in TCM with chakras’ energy centers and measuring the chakra, the author will be measuring the internal massive organs energy. Purpose: To demonstrate that there are chakras’ energy deficiencies chronically present in the body of the patient with breast cancer. Also, to analyze the importance of treating the subject systemically, through the replenishment of chakras’ energy centers. Methods: two cases report, both were female patients (42 and 56years old), with the diagnosis stress and anxiety in the first and the second with diagnosis of sub retinal fluid retention, both patients with past history of breast cancer twenty and six years ago, removed with surgery. Chakras’ energy measurement through radiesthesia procedure was done. Results: all the chakras were in the lowest level of energy, rated in one out of eight. Conclusion: patients with history of breast cancer have chakras’ energy centers deficient in energy and the replenishment of these chakras’ is the major importance to prevent future formation of metastasis, new cancer in other sites or the formation of any chronic diseases.